Safe Supply Streaming Portfolio Company, Safety Strips, Provides Corporate Update
Toronto, Ontario--(Newsfile Corp. - May 7, 2024) - Safe Supply Streaming Co Ltd. (CSE: SPLY) (FSE: QM4) (OTCQB: SSPLF) ("Safe Supply"...
Addiction
Awakn Life Sciences Discusses Filing of Financial Statements
Toronto, Ontario--(Newsfile Corp. - May 2, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or...
Safe Supply Streaming: Pioneering Solutions in the Addiction Crisis through Strategic Partnerships and Innovation
Toronto, Ontario--(Newsfile Corp. - May 2, 2024) - Safe Supply Streaming Co Ltd. (CSE: SPLY) (FSE: QM4) (OTCQB: SSPLF) ("Safe Supply"...
STALICLA initiates U.S. Phase 3 enabling DDI study of STP7 (Mavoglurant) to treat cocaine use disorder
Geneva, Switzerland, May 2, 2024 – STALICLA SA, a late-stage biotechnology company specializing in precision medicine for brain disorders, announces...
VitalHub Announces Q1 2024 Conference Call Date
TORONTO, May 02, 2024 (GLOBE NEWSWIRE) -- VitalHub Corp. (the "Company" or "VitalHub") (TSX: VHI) (OTCQX:VHIBF) is pleased to announce...
Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual Film
Libervant is the first and only FDA approved orally administered rescue product for the treatment of seizure clusters in patients...
Ibogaine By David Dardashti Acknowledges Importance of Body Image in Addiction and Mental Health Recovery
Comprehensive Treatment of Addiction and Mental Health Requires a Focus on Self-Love Alcohol algorithm New procedures to help those who...
Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office
GLEN ALLEN, Va., April 22, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage...
Ibogaine By David Dardashti Announces New Algorithm For Alcohol Addiction
Revolutionary Method to Combat Alcoholism and Restore Quality of Life Alcohol algorithm New procedures to help those who struggle. MIAMI,...
Ibogaine by David Dardashti Introduces New Algorithm for Methadone Addiction
Algorithm Varies Slightly from Suboxone and Focuses on Continuously Dosed Ibogaine Treatment Methadone algorithm Ibogaine by David Dardashti is improving...
Ibogaine By David Dardashti Introduces New Algorithm for Depression Treatment
A Revolutionary Advancement in Depression Treatments Ibogaine by David Dardashti A new algorithm to help combat depression MIAMI, April 21,...
Mobilize Recovery Cross-Country Bus Tour Galvanizes Community, Prevents Overdoses
Fifteen cities to host events in partnership with iHeartMedia, Meta, SAMHSA, Inseparable, and dozens of community partners coinciding with nationwide...
Revolutionizing Pain Management in Urgent Care Centers
United Pain Urgent Care is Pioneering Non-Opioid Solutions for Acute Pain RENO, NV / ACCESSWIRE / April 17, 2023 /...
BrainsWay Expands Deep TMS™ Access in Israel Following Significant Increase in Reimbursement Rates
Company Announces 11th Recent System Installed in Israel, with More Expected this YearBURLINGTON, Mass. and JERUSALEM, April 17, 2024 (GLOBE...
Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
Tel Aviv, Israel / Vancouver, Canada, April 17, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind”...
atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
BPL-003 is Beckley Psytech’s novel patent-protected benzoate salt formulation of 5-MeO-DMT that is administered intranasally.BPL-003 was shown to be safe...
Awakn Life Sciences Announces Closing of Tranche of Private Placement
Toronto, Ontario--(Newsfile Corp. - April 17, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or...
Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder
Findings underscore the liver safety of AD04 as compared to placebo in the prior Phase 3 clinical trialGLEN ALLEN, Va.,...
Chromocell Issues Letter to Stockholders from Chief Executive Officer
FREEHOLD, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer...
Clearmind Medicine CEO Issues Letter to Shareholders
Vancouver, Canada, April 09, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq:CMND), (FSE: CWY0) (“Clearmind” or the “company”), a clinical-stage...